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Abstract:  Biotechnology has demonstrated its importance for health development, especially in the discovery of new drugs and production of 
vaccines. On account of the occurrence of many diseases that have killed millions of people in the world, vaccines were developed to control 
infections and prevent diseases caused by viruses, bacteria, protozoans and fungi, and even eradicate them, as is the case of smallpox. 
Vaccines can be of first, second and third generation. Currently, vaccine manufacturing can be directed to the use of DNA containing the 
gene that encodes an antigenic protein. The present work is a literature review, with the objective to present the first-, second- and third-
generation vaccines, as well as to make an analysis of the use of these vaccines in Brazil.
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Introduction
Biotechnology, according to the Office of Technology Assessment 
(OTA),1 can be defined as any technique that uses living organisms (or 
their parts) to obtain or modify products, improve plants and animals, or 
develop microorganisms for specific uses. Modern Biotechnology has a 
wide application in the health industry, attracting interest from scientists 
for production of drugs and vaccines, thus contributing to the economic 
development and, especially, to growth of pharmaceutical industry.2
Science and technology complement each other, integrating basic 
and applied sciences with other technologies such as molecular biology, 
cellular biology, immunological techniques, biochemistry and microbial 
fermentation processes.3
Advances in the industrial sector has brought many benefits to so-
ciety, but it is worth saying that, among several consequences, mas-
sive migration of the population from countryside to urban centers has 
occurred, diminishing quality of life due to lack of basic sanitation and, 
consequently, causing more diseases for people and animals. In the 
19th century, 80% of children died of various diseases before their 10th 
birthday.3 In addition, millions of deaths have been recorded as a result of 
human contamination by viruses and bacteria, causes of diseases such 
as yellow fever, pertussis, smallpox, tetanus, diphtheria, measles, po-
lio, rubella, hepatitis, bubonic plague, cholera, rabies, chickenpox, and 
mumps, which are among the most well-known diseases.
In order to control and prevent infections and diseases, scientists 
discovered vaccines, which were based on the principle that the indi-
vidual’s contact with the antigen produced an immune response.4 As a 
result, several studies have been conducted to develop more effective 
vaccines. Genetic manipulation established by modern Biotechnology 
has modified in different ways research and development of these vac-
cines, which have been classified as first second and third generation.5
First generation or traditional vaccines are produced with live atten-
uated microorganisms, i.e., the weakened pathogen itself is inoculated 
into the patient. Vaccines against smallpox, polio, measles, rubella, ad-
enovirus and tuberculosis can be included in this type. Second-gen-
eration vaccines arose from the idea that vaccines can be obtained by 
toxins produced by microorganisms that cause diseases. These toxins, 
called toxoids, can be inactivated and become recognized by the host’s 
immune system. They can also be produced with purified polysaccha-
rides. The recombinant proteins are used as a source for the antigens to 
be incorporated into the formulations.5 In the 1990s, third-generation 
vaccines emerged, in which the material inoculated into the patient is not 
the attenuated or dead pathogen, but its DNA containing the gene that 
encodes an antigenic protein. However, it is necessary to have an agent 
that introduces DNA into the patient’s cells, which are called DNA vec-
tors, for the vaccine to present any effect.6
The history of vaccine, from its discovery by Edward Jenner in the late 
18th century7 until the present day, has provided the world’s population 
with greater safety, health, and has undoubtedly saved billions of people 
from various diseases. Vaccine production in Brazil deserves special 
consideration, as the country is a global reference due to the efforts of 
the National Immunization Program, Butantan and Fiocruz Institutes.8,9
It is important to remember that the first vaccine reported was for 
smallpox, discovered in 1789. This vaccine arrived in Brazil almost one 
century later, in 1887, and, only in 1922, the Oswaldo Cruz Institute 
began to produce it. Smallpox eradication became a goal by the World 
Health Organization from the 1950s onwards, but it was eradicated 
only in the 1970s. The BCG vaccine was discovered in 1909 and only 
began to be used in Brazil in 1925. Production and use of the vaccine 
against yellow fever started to be produced in 1937 in Brazil. Currently, 
Fiocruz is the largest producer of this vaccine. The vaccine against 
poliomyelitis, discovered in 1949 by Jonas Salk, was later developed 
for oral application by Albert Sabin and started to be used in 1961. 
The discovery of the vaccine against rubella occurred in 1969. In 1963, 
the vaccine against measles was developed. In Brazil, this vaccine was 
effectively implemented in 1973 with the National Immunization Plan 
(NIP), but only in 1992 the fight against this disease was defined as a 
public health policy priority. The second dose of the triple viral vaccine 
(measles, rubella and mumps) was introduced in 2004.10
In addition, Brazil has adopted a successful vaccination strategy.8 
Brazil’s National Immunization Program (NIP) is considered one of 
the most comprehensive among developing countries. For example, 
Brazil received the poliomyelitis eradication certificate in 1994 and 
also pioneered the introduction of rotavirus, conjugate pneumococcal, 
meningococcal meningitis, and conjugate C serogroup vaccines in 2007, 
and vaccination against the H1N1 pandemic influenza in the second half 
of 2010.9 Tables 1, 2, 3 and 4 show the vaccination calendar in Brazil for 
children, teenagers, pregnant women, and travelers, respectively. Table 
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Child
Age Vaccine Avoidable diseases Dose
At birth
BCG-ID Prevents severe forms of tuberculosis 
(miliary and meningeal)
Single dose
Hepatitis B Single dose
2 months
Pentavalent (DTP + Hib + 
Hep. B)
Prevents diphtheria, tetanus, pertussis, hep-
atitis B, meningitis and Hib infections
1st dose
Inactivated polio (VIP) Prevents polio (infantile paralysis)
Pneumococcal 10-valent 
(conjugated)
Prevents pneumonia, otitis, meningitis and 
other diseases caused by Pneumococcus
Human rotavirus (VORH) Prevents rotavirus diarrhea
3 
months




Pentavalent (DTP + Hib + 
Hep. B)
Prevents diphtheria, tetanus, pertussis,
hepatitis B, meningitis and Hib infections
2nd dose
Inactivated polio (VIP) Prevents polio (infantile paralysis)
Pneumococcal 10-valent 
(conjugated)
Prevents pneumonia, otitis, meningitis and 
other diseases caused by Pneumococcus
Human rotavirus (VORH) Prevents rotavirus diarrhea
5 
months




Pentavalent (DTP + Hib + 
Hep. B)
Prevents diphtheria, tetanus, pertussis, hep-
atitis B, meningitis and Hib infections
3rd dose
Inactivated polio (VIP) Prevents polio (infantile paralysis) 3rd dose
12
months
Triple Viral (SCR) Prevents measles, mumps and rubella 1st dose
Meningococcal C Prevents pneumonia and meningococcemia 
(generalized infection)
Reinforcement
Pneumococcal 10-valent Prevents pneumonia, otitis, meningitis and 




Triple Bacterial (DTP) Prevents diphtheria, tetanus and whooping 
cough
1st Reinforcement
Oral poliomyelitis (OPV) Prevents polio (infantile paralysis) 1st Reinforcement
Hepatitis A Prevents hepatitis A Single dose




Triple Bacterial (DTP) Prevents diphtheria, tetanus and whooping 
cough
2nd Reinforcement
Oral poliomyelitis (OPV) Prevents polio (infantile paralysis) 2nd Reinforcement
9 years* Human Papillomavirus
(HPV)
Prevents papilloma, human virus that
causes cancers and genital warts
Two doses in a pe-
riod of six months
* It may be applied up to 14 years 11 months and 29 days
Table 1 - Vaccination calendar for children.Source: Adapted from the Brazilian Ministry of Health’s website.11
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Adolescent
Age Vaccine Avoidable dis-
eases
Dose





Prevents papilloma, human virus that 
causes cancers and genital warts
Two doses six 
months apart
11 to 14 years 
(boys and girls)
Meningococcal C Prevents meningitis and meningo-
coccemia (generalized infection)
A booster or 
single dose
11 to 19 years
Hepatitis B 
(recombinant)
Prevents hepatitis B Three doses**
Adult double bacterial 
(dT)
Prevents diphtheria and tetanus One dose every ten 
years**
Triple viral (SCR) Prevents measles, mumps and rubella Two doses**
** According to the vaccination situation
Table 2 - Vaccination calendar for teenagers.Source: Adapted from the Brazilian Ministry of Health’s website.11
Pregnant
Vaccine Avoidable diseases Dose
Hepatitis B 
(recombinant)
Prevents hepatitis B Three doses**
Adult double 
bacterial (dT)
Prevents diphtheria and tetanus Two doses**
Triple acellular 
bacterial (dTpa)
Prevents diphtheria, tetanus and whooping cough
One dose with each 
pregnancy (from the 
20th gestational week)
** According to the vaccination situation
Table 3 -  Vaccination calendar for pregnant women.Source: Adapted from the Brazilian Ministry of Health’s website.11
Traveler
Vaccine Avoidable diseases Dose
Hepatitis B (recombinant) Prevents hepatitis B Three doses**
Adult double bacterial (dT) Prevents diphtheria and tetanus Two doses**
Yellow fever Prevents yellow fever Single dose (9 months to 59 
years of age)***
Triple viral (SCR) Prevents measles, mumps and rubella
Two doses (1 to 29 years) 
and one dose (30 to 49 of 
age)**
** According to the vaccination situation
*** Only applied to residents and/or travelers to areas with vaccination recommendation (ACRV)
Table 4 - Vaccination calendar for travelers.Source: Adapted from the Brazilian Ministry of Health’s website.11
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Children (6 months to under 6 years of age) April 10 to May 31
Elderly people (60 years of age or older), those who 
have recently given birth (up to 45 days after birth), 
health workers, teachers in public and private 
schools, indigenous peoples, groups with chronic 
noncommunicable diseases and other special 
clinical conditions, adolescents and young people 
between 12 and 21 years of age under social and 
educational measures, people deprived of their 
liberty and prison system employees
April 22 to May 31.
D” day of mobiliza-
tion: May 4th
Table 5 - Calendar of the vaccination campaign. Source: Adapted from the Brazilian Ministry of Health’s website.11.
Objectives
The objectives of this work are to present the first-, second- and 
third-generation vaccines as well as to make an analysis of the use of 
these vaccines in Brazil.
Methodology
For this review work, a survey of the articles with the highest number 
of accesses and easy acquisition within databases such as Google Scholar 
and PubMed was carried out. The method of bibliographic research 
related to the subject was used and then the most relevant data of the 
main themes related to Biotechnology and vaccines were collected. 




Biotechnology has contributed to a number of significant changes 
in the area of biology and health, especially in the field of genetics. 
Gene manipulation techniques, such as gene sequencing, have altered 
scientific research for the health sector in different ways. Some areas to 
which research is currently focused are: synthetic biology (creation of 
“customized” organisms), three-dimensional bioprinting and uses and 
applications in the area of neurotechnology.12
The insertion of Biotechnology in the pharmaceutical industry has 
enabled an increase in the number of therapeutic compounds, greater 
knowledge of the processes causing diseases, more accurate diagnoses 
and more efficient delivery mechanisms, such as recombinant DNA for 
therapeutic protein production, hybridization for monoclonal antibody 
production and techniques for cloning and manipulation of stem cells.2
Another area of health that has benefited from technological 
advances is the area of vaccines. Biotechnology has brought changes in 
the way vaccines are produced, such as the discovery of new antigens, 
adjuvants, vectors or delivery systems. The production process of a drug 
or vaccine can be briefly divided into three stages: a) production of the 
active ingredient, which is the substance responsible for the therapeutic 
action; b) formulation, a phase in which the active ingredient is mixed 
with other substances (adjuvants) in order to adapt characteristics of the 
final product, such as solubility, effect duration, stability, and absorption 
and elimination by the body; and c) packaging, i.e., the packaging of the 
finished product in quantities for final consumption.5
Many vaccines are still administered by methods created in the 
past centuries. It is expected from biotechnological advances that safer 
and more effective vaccines will be produced and made available to an 
increasing number of people.5
The development of the third-generation vaccines (called DNA 
vaccines) was possible due to technological advances in Biotechnology. 
Although their use in humans is not yet approved, such vaccines have 
been applied against diseases such as cancer.4
Vaccine concepts
Vaccination or immunization is the process of developing the body’s 
immunity or defense against infections with antigens (substances that 
stimulate the body to produce antibodies against the infectious agent – 
viruses, bacteria or parasites). Vaccines can be produced from dead or 
attenuated microorganisms or from their components (first generation). 
However, in some cases, the disease may occur due to a toxic substance 
produced by the microorganism. Then, the vaccine needs to neutralize 
this toxin (second generation). In other cases, however, the problem is 
not the virus or the bacteria, but the quantity of them inside the host. 
Therefore, its multiplication must be controlled.13 Figure 1 shows the 
three generations of vaccines.14
An open access article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work 
is properly cited.
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The three generations of vaccine
First generation
First-generation vaccines are produced with antigens of only one 
infectious agent, which produces protective antibodies only for that 
agent, such as the diphtheria vaccines. They can also be combined, 
which are those that have two or more agents, such as diphtheria-
tetanus or triple viral (against measles, mumps and rubella). Vaccines can 
also be conjugated, i.e. bacterial antigens are bound to protein carriers 
(polysaccharides) generating a long-lasting antibody response, such as 
pneumococcal vaccines.13
One of the first-generation vaccine production techniques is the 
inactivation of microorganisms (dead and inactive), such as antipertussis, 
typhoid fever, bubonic plague, Salk (injectable poliomyelitis), hepatitis 
A, influenza, rabies, whooping cough, anthrax and cholera vaccines. 
First-generation vaccines can also be produced with live attenuated 
microorganisms, such as BCG against tuberculosis.15,16
Smallpox is a disease that has devastated populations for many 
years, but is no longer considered a concern for humanity. Its eradication 
was registered in 1977. Vaccine against smallpox is considered the 
basis of immunology, suggesting that virus infection conferred specific 
immunity to the disease.17 Vaccine against smallpox is not available to the 
public and the virus no longer exists in nature. The vaccine is produced 
from the attenuated vaccinia virus, a poxvirus similar to smallpox virus, 
but less harmful.18
Vaccine against yellow fever, produced in Brazil since 1937 and 
internationally recognized, also consists of attenuated viruses, more 
specifically from the attenuated strain of the 17D virus of the Flavivirus genus.20
Another disease against which an attenuated virus vaccine is used is 
measles. This is a highly contagious viral disease that occurs throughout 
the world. The infection is characterized by fever, malaise, cough, coryza 
and conjunctivitis, followed by exanthema.20 Humans are the sole host.21 
In Brazil, the vaccine was introduced in 1960. It is contained in the triple 
viral (measles-mumps-rubella), which contains weakened measles, 
rubella and mumps live virus and is currently recommended for children 
aged 12 months, with application of the second dose between four and six 
years of age or in any consultation after 12 months of life, with a minimum 
interval of four weeks. The Ministry of Health reports that Brazil was 
awarded a certificate of measles elimination by the Pan-American Health 
Organization in 2016, but states that the country has struggled to maintain 
this certificate, since two outbreaks had already been identified in 2018.22
Rubella is a disease caused by viruses of the Rubivirus genus which 
is transmitted by direct contact through tiny drops of saliva released 
into the air when the infected person coughs, sneezes or talks, or from 
the mother to the fetus through blood circulation. The vaccine, which is 
part of the triple viral (measles-mumps-rubella), is a combination of live 
attenuated viruses.23
Poliomyelitis, also called infantile paralysis, is an acute contagious 
disease caused by poliovirus, which can infect children and adults through 
direct contact with feces or with secretions eliminated by the mouth of 
sick people and can cause paralysis. In Brazil, the last case of infection 
by the wild poliovirus occurred in 1989 in the city of Souza, in the state 
of Paraíba. The strategy adopted for the virus elimination in the country 
was centered on conducting mass vaccination campaigns with oral polio 
vaccine (OPV). Sabin attenuated virus strains types I, II and III was used.19
Another immunization obtained by an attenuated strain is the 
vaccine against tuberculosis. The BCG vaccine (Calmette and Guérin 
bacillus) originates from avirulent strains of Mycobacterium bovis, after 
genetic mutation and with immunogenic protective properties against 
tuberculosis. In Brazil, BCG was applied in 1925 and was orally used until 
1973, when it started to be intradermally administered, as determined 
by the Ministry of Health. There is a consensus in the literature that 
intradermal BCG is effective against severe forms of tuberculosis, such 
as meningoencephalic and miliary.25
The third part of the triple bacterial vaccine was the result of 
immunizers developed in 1942 by Louis Sauer, Pearl Kendrick and Grace 
Eldering against pertussis. Sauer et al. found that the vaccine was most 
effective in uniting diphtheric and tetanic toxoids.26 Thus, the triple 
Figure 1 - The three generations of vaccines.Source: Adapted from Gorry et al. (2017). 
Biotechnology and vaccines...
59 INTERNATIONAL JOURNAL OF ADVANCES IN MEDICAL BIOTECHNOLOGY - IJAMBVol. 2 N.2, 2019
bacterial vaccine emerged. According to the Ministry of Health, pertussis 
is a respiratory infection, transmissible and caused by the bacteria 
Bordetella pertussis, a Gram-negative and aerobic coccobacillus. 
Pertussis transmission occurs mainly by direct contact of the patient with 
an unvaccinated person through droplets eliminated through coughing, 
sneezing or talking. Pertussis is produced with dead and inactivated 
microorganisms.27
Second generation
After the emergence of attenuated and inactive vaccines, second-
generation recombinant vaccines emerged, proving that for individuals 
to be protected against an infectious agent, it is not necessary for him/
her to produce antibodies against all the antigens of the microorganism. 
Recombinant vaccines are obtained by genetic engineering, by inserting 
a gene that produces an immunogenic protein in a microorganism.28 
The identification of one or two proteins crucial for immune protection is 
sufficient to create a second-generation vaccine in which the immune 
response is induced by a specific isolate antigen. The antitetanic, 
antidiphtheric, antihepatitis B vaccines and those for the control of 
meningococcal meningitis and pneumonia are found in this group.5
The first approved recombinant vaccine was the vaccine against 
hepatitis B, which only began to be produced in cell culture systems in 
1986.29 Among the second-generation vaccines there is the vaccine 
against meningococcal meningitis, caused by the bacteria Neisseria 
meningitidis. The Cuban vaccine, the first in the world with proven efficacy 
against the disease caused by meningococci B, is based on proteins from 
the external membrane of this microorganisms capable of inducing 
antibodies against all tested Neisseria meningitidis pathogenic groups. 
To combat meningococcal meningitis, a conjugate vaccine is used, which 
is a differentiated type of vaccine because it was specially developed to 
combat encapsulated bacteria that have a protective membrane around 
their cell structure. These capsules are made of polysaccharides, which 
ensure a great resistance of the bacteria against the human immune 
defense system. Because of this, when producing a vaccine against 
encapsulated bacteria, it is necessary to wrap the protective capsule 
with a protein. So, the antibodies can penetrate the bacteria destroying 
and guaranteeing health for the vaccinated individual.30
Other second-generation vaccines that act against toxins are 
the antitetanic and antidiphtheric ones.4 Diphtheria is a transmissible 
disease caused by bacteria that affect tonsils, pharynx, larynx, nose 
and occasionally other parts of the body such as skin and mucous 
membranes. The main form of prevention against the disease is through 
the pentavalent vaccine (diphtheria, tetanus, pertussis, hepatitis B 
and Haemophilus influenzae type B). Since the 1990s, Brazil has shown 
an important reduction of the incidence of cases by expanding the 
vaccine coverage. In that decade, the incidence reached 0.45/100,000 
inhabitants, decreasing as the coverage increased. Between 2008 
and 2017, only 10 deaths caused by the disease occurred in Brazil31. 
The Butantan Institute reports that the antidiphtheric serum is the only 
effective drug for neutralization of toxins produced by the diphtheria 
bacillus (Corynebacterium diphtheriae). Serum, when applied to 
a patient diagnosed with diphtheria, acts by neutralizing the toxin 
produced by the diphtheria bacillus. By applying the antidiphtheric 
serum, the antibodies contained in the serum specifically bind to the 
toxin and thus neutralize its toxic actions in the body.32
According to the Butantan Institute, the antitetanic serum has the 
function of neutralizing the toxins produced by the tetanus bacillus 
(Clostridium tetani) and is intended for the treatment of patients with 
accidental or neonatal tetanus, for the prevention of tetanus in patients 
with injuries, not vaccinated, with uncertain vaccination or with less than 
three doses, or vaccinated with three doses, the last dose being for more 
than 10 years. The specific immunoglobulins (antibodies) generated by 
the immunization of horses produce the purified antitetanic serum that 
acts by neutralizing the tetanic toxins that are in the blood circulation.32 
Tetanus is a noncontagious acute infectious disease caused by fixation 
in the nervous system of exotoxins of Clostridium tetani. Clinically, 
tetanus manifests by hypertonia of the jaw and neck muscles, and may 
reach progressive muscle stiffness and generalized muscle contracture, 
affecting the rectum-abdominal muscles and the diaphragm, leading to 
respiratory failure.33
Third generation
Gene (or third-generation) vaccines are so called because they are 
composed of DNA-coding plasma proteins of pathogens, allergens 
and tumors and encode potentially immunogenic antigens using gene 
fragments.34
DNA vaccines are so called because the antigen is synthesized in 
vivo after the direct introduction of their encoding sequences. They 
present a unique method of immunization that can solve many of the 
shortcomings of traditional vaccines. Other advantages are low cost, 
relative facility of manufacture, thermal stability, possibility of obtaining 
multivalent vaccines and rapid development of new vaccines in response 
to new strains of pathogens.35 These vaccines are being evaluated as 
prophylactic and therapeutic treatments for infectious diseases, allergies 
and cancer. Plasmids that encode normal human proteins are also being 
tested as vaccines and treatments for autoimmune diseases.36 Since 
cells do not accept receiving DNA from different cells, a vector playing 
this role is required, as is the case of DNA vectors. This must occur for 
DNA to encode an antigenic protein. The easiest method to produce and 
characterize gene transferring is the direct application of pure plasmid 
DNA. It is often applied by intramuscular injection, although it can be 
administered by several other routes such as oral mucosa, vaginal and 
epidermal layer by “gene guns”.35
Although rodent research shows efficient immunogenicity. the 
lower efficacy of DNA vaccines in experiments on big animals, including 
humans, is due to the inefficient delivery of DNA plasmid to cells.37 Ulmer 
et al. found it was sufficient to transplant stably transfected myoblasts 
expressing the influenza nucleoprotein to induce cell-mediated 
protective immunity. The mice used in the test produced high titer 
antibodies and cytotoxic T lymphocytes, which protected them from a 
lethal cross-strain test with influenza A virus. The authors concluded 
that the expression of the antigen by muscle cells is sufficient to confer 
protective immunity mediated by cells.38
Plasmid DNA vaccine has also been widely explored for immunization 
against tuberculosis. Zhang et al. produced a plasmid DNA vaccine 
that encodes Ag85A and GM-CSF genes and provides immunological 
protection against the Mycobacterium tuberculosis bacillus in mice 
tests. The authors showed that the use of electroporation allows a single 
intramuscular injection of DNA to be as effective as repeated injections 
of DNA in activating Ag85A-specific T-cells.39 Until 2015, four DNA 
vaccines have been licensed for veterinary uses. They are vaccines against 
West Nile virus in horses, against infectious hematopoietic necrosis virus 
in salmon and for the treatment of melanoma in dogs (malignant neoplasia).40
The biotechnological advance of vaccines, which were previously 
manufactured with inactivated, live attenuated and sub-unit (first 
and second generation) micro- organisms, is evident. By 2020, other 
technologies such as a better comprehension of the innate immune 
system and the development of new adjuvants should contribute to the 
improvement of existing vaccines and the development of new vaccines 
to prevent and treat many types of infections.41
While development brings benefits to society such as increased 
employment opportunities and a warming economy, human health is the 
first to suffer the malefic consequences of reduced quality of life due to a 
lack of basic sanitation in a scenario of mass migration to urban centers 
as a result of industrialization. Advances in Biotechnology have made 
it possible to develop new technological products, including vaccines, 
which are increasingly effective in protecting health.
Brazil is one of the countries with the highest coverage of infantile 
and adult vaccination, as it has presented successful vaccination 
strategies. The national immunization program is considered an example 
for the whole world.
Immunization by the attenuated pathogens discovered by Edward 
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Jenner has given the world’s population more security, health and a long-
life expectancy. Smallpox, poliomyelitis, rubella, measles, diphtheria and 
pertussis are examples of diseases that were, at some point in human 
history, pandemics or epidemics that ravaged continents for decades 
or even centuries, and today are eradicated or with regional foci and 
very low mortality rates. However, diseases such as tuberculosis, AIDS, 
Ebola, influenza, yellow fever and cholera continue to affect millions (if 
not billions) of people because first- and second-generation vaccine 
immunization methods are ineffective against the microorganisms that 
cause such diseases.
One of the areas in which Biotechnology has made a great progress 
is health. New technologies, such as gene sequencing, have made it 
possible to discover new routes to eradicate viruses and bacteria that 
are harmful to human health. Manipulation of DNA has led to an evolution 
in treatment and prevention of diseases, despite ethical questions that 
may be raised. DNA or third-generation vaccines, although currently 
ineffective, are promising in the fight against diseases such as cancer 
and AIDS. Many researches have been carried out in the area of 
Biotechnology with the objective of bringing more safety and efficacy in 
the combat and eradication of diseases considered today without cure.
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